Lancet: Risk of cardiovascular events and rofecoxib
Posted by Clark Venable on 11/27/2004
Lancet: Risk of cardiovascular events and rofecoxib: cumulative meta-analysis (pdf)
""Findings: We identified 18 randomised controlled trials and 11 observational studies. By the end of 2000 (52 myocardial infarctions, 20742 patients) the relative risk from randomised controlled trials was 2·30 (95% CI 1·22-4·33, p=0·010), and 1 year later (64 events, 21432 patients) it was 2·24 (1·24-4·02, p=0·007). There was little evidence that the relative risk differed depending on the control group (placebo, non-naproxen NSAID, or naproxen; p=0·41) or trial duration (p=0·82). In observational studies, the cardioprotective effect of naproxen was small (combined estimate 0·86 [95% CI 0·75-0·99]) and could not have explained the findings of the VIGOR trial.""
This post has 0 replies
See full thread
